AIM疫苗在中国获得新流感疫苗和改良破伤风疫苗的批准。 AIM Vaccine gets Chinese approval for a new influenza vaccine and an improved tetanus shot.

新的流感疫苗和改良破伤风疫苗已获得中国医疗当局的批准。 AIM Vaccine has received approval for a new influenza vaccine and an improved tetanus vaccine from China’s medical authorities. 使用MDCK细胞制造的流感疫苗是中国批准的第一个此类疫苗,比现有疫苗的安全和生产质量更好。 The influenza vaccine, made using MDCK cells, is the first of its kind approved in China and offers better safety and production quality than existing vaccines. AIM疫苗还计划为多种疾病开发一种综合疫苗,以减少儿童需要的射击次数。 AIM Vaccine also plans to develop a combined vaccine for multiple diseases, aiming to reduce the number of shots needed for children. 这些进展可以带来可观的收入增长,加强公司在疫苗市场中的地位。 These advancements could bring significant revenue growth and strengthen the company's position in the vaccine market.